Literature DB >> 2937504

Adverse drug reactions to first- and second-generation antidepressants: a critical evaluation of drug surveillance data.

L G Schmidt, R Grohmann, B Müller-Oerlinghausen, H Ochsenfahrt, P S Schönhöfer.   

Abstract

We reviewed data on adverse drug reactions (ADRs) to first- and second-generation antidepressants, recorded by two different drug surveillance systems. The rate of ADRs that led to discontinuation of the drug in the individual case, assessed within a multi-centered hospital-based drug monitoring system (AMUP), was significantly higher in case of exposure to tricyclics (7.4%) than with the second-generation drugs (3.1%). On the basis of voluntary reports to the Medicines Commission of the German Medical Profession (AMK), profiles of ADRs to the drugs under survey were constructed and compared with data compiled by the WHO. The types of ADRs varied more between second-generation drugs than between tricyclics. Special attention was paid to rare but serious ADRs (e.g. seizures during treatment with maprotiline, and blood dyscrasias attributed to mianserin).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937504     DOI: 10.1192/bjp.148.1.38

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Which antidepressant?

Authors:  K Matthews; J M Eagles
Journal:  Br J Gen Pract       Date:  1991-03       Impact factor: 5.386

2.  Relative cytotoxicity of psychotropic drugs in cultured rat hepatocytes.

Authors:  U A Boelsterli; P Bouis; P Donatsch
Journal:  Cell Biol Toxicol       Date:  1987-09       Impact factor: 6.691

3.  Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.

Authors:  Ma-Li Wong; Chuanhui Dong; Deborah L Flores; Monika Ehrhart-Bornstein; Stefan Bornstein; Mauricio Arcos-Burgos; Julio Licinio
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

4.  Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.

Authors:  Jiewei Liu; Yuqi Cheng; Ming Li; Zhijun Zhang; Tao Li; Xiong-Jian Luo
Journal:  Neuropsychopharmacology       Date:  2022-09-16       Impact factor: 8.294

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.